Nano-X Imaging Ltd.
Nano-X Imaging Ltd. Ordinary Shares represents the equity of Nano-X Imaging Ltd., a medical imaging technology company focused on developing and commercializing digital X-ray-based imaging systems and related healthcare services. The company’s current offerings center on the Nanox platform, which combines the Nanox.ARC imaging system with software and cloud-enabled tools such as Nanox.CLOUD for image management, radiologist workflow support, review, annotation, billing, and reporting. Nano-X Imaging also operates in AI-driven medical imaging applications and teleradiology services, serving healthcare providers that need diagnostic imaging solutions and connected service workflows. Headquartered in Petach Tikva, Israel, Nano-X Imaging Ltd. is positioned within the healthcare technology market, where its products are designed to broaden access to medical imaging and integrate hardware, software, and services into a single platform.
$0.45
-$0.04 (-7.74%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-466.16% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 15.4% YoY with margins expanding 36.8pp.
ROIC dropped from -22.39% to -27.87%, capital efficiency is deteriorating. Negative free cash flow of -$45M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$16M
▲ +15.4% YoY
Net Income (TTM)
-$117M
▼ -40.2% YoY
Op. Margin
-653.27%
▲ +36.8pp YoY
ROIC
-27.87%
▼ -5.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$52M
▼ -14.3% YoY
Op. Cash Flow (TTM)
-$47M
▼ -11.1% YoY
Net Debt
-$52M
Net Cash Position
Cash & Equiv.
$60M
3Y CAGR: +14.9%
Continue Research
Is Nano-X Imaging (NNOX) overvalued?
Nano-X Imaging (NNOX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nano-X Imaging scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Nano-X Imaging a high-quality business?+
Nano-X Imaging scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -653.3% operating margin and a -27.9% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Nano-X Imaging a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh NNOX's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Medical Devices
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.